Brzoska M, Langer K, Coester C, Loitsch S, Wagner T O F, Mallinckrodt C v
Department of Pulmonology, Medical Clinic of Johann-Wolfgang-Goethe University Frankfurt am Main, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
Biochem Biophys Res Commun. 2004 May 28;318(2):562-70. doi: 10.1016/j.bbrc.2004.04.067.
Nanoparticles are able to enhance drug or DNA stability for purposes of optimised deposition to targeted tissues. Surface modifications can mediate drug targeting. The suitability of nanoparticles synthesised out of porcine gelatin, human serum albumin, and polyalkylcyanoacrylate as drug and gene carriers for pulmonary application was investigated in vitro on primary airway epithelium cells and the cell line 16HBE14o-.
The uptake of nanoparticles into these cells was examined by confocal laser scan microscopy (CLSM) and flow cytometry (FACS). Further the cytotoxicity of nanoparticles was evaluated by an LDH-release-test and the inflammatory potential of the nanoparticles was assessed by measuring IL-8 release.
CLSM and FACS experiments showed that the nanoparticles were incorporated into bronchial epithelial cells provoking little or no cytotoxicity and no inflammation as measured by IL-8 release.
Based on their low cytotoxicity and the missing inflammatory potential in combination with an efficient uptake in human bronchial epithelial cells, protein-based nanoparticles are suitable drug and gene carriers for pulmonary application.
纳米颗粒能够增强药物或DNA的稳定性,以优化其在靶向组织中的沉积。表面修饰可介导药物靶向。研究了由猪明胶、人血清白蛋白和聚烷基氰基丙烯酸酯合成的纳米颗粒作为药物和基因载体用于肺部应用时,在原代气道上皮细胞和16HBE14o-细胞系上的体外适用性。
通过共聚焦激光扫描显微镜(CLSM)和流式细胞术(FACS)检测纳米颗粒进入这些细胞的摄取情况。此外,通过乳酸脱氢酶释放试验评估纳米颗粒的细胞毒性,并通过测量白细胞介素-8的释放来评估纳米颗粒的炎症潜力。
CLSM和FACS实验表明,纳米颗粒被支气管上皮细胞摄取,引起的细胞毒性很小或没有,并且通过白细胞介素-8释放测量显示没有炎症。
基于其低细胞毒性、无炎症潜力以及在人支气管上皮细胞中的有效摄取,基于蛋白质的纳米颗粒是适用于肺部应用的药物和基因载体。